Investors are turning to biotechnology stocks and other stocks, rather than large cap stocks with high market capitalization.

This week, the emerging markets have seen an increase. The growth market index rose by almost the same rate as the Nikkei average, which was +3.12%. The growth market index rose by +3.05% and the growth market 250 index rose by +3.35%. The trading volume is slightly over 100 billion yen, and with few participants, the investor sentiment was stimulated by the rise of prime stocks due to the rise in US stocks, and the growth market also rose. Biotechnology stocks and others are attracting attention, rather than large cap stocks, and the growth market 250 index has become heavy at the 200-day moving average.

In the top market capitalization stocks, GENDA <9166> was bought based on positive securities company reports, and GNI Group <2160> continued to be viewed as a buy due to high evaluations by securities companies. In addition, after the earnings announcement, the selling pressure on Timmey <215A> intensified, but it finally ended. Apart from the top market capitalization stocks, biotechnology stocks such as Anges <4563>, SBI Bio <4592>, Qualipse <4894>, and Canvas <4575> continued to attract attention.

There are 7 IPOs scheduled for next week, and there is a possibility that the search for recent IPO stocks will become active.

Next week's emerging market is expected to see a heavier upward trend due to a decrease in the yen and a dominant market of large cap stocks. There is a possibility that the growth market 250 index could reach the 200-day moving average line of 674 points, but with the direction of major stocks diverging and trading volume not increasing, it is unlikely that there will be a strong market development that surpasses the 200-day moving average. On the 26th, which is the final day for rights-taking, individual investors are expected to focus on searching for dividends and benefits centered around large cap stocks, leaving the growth market on the sidelines. Short-term funds continue to flow into biotechnology stocks such as Anges, Qualipse, and Noel Immun <4893>, and it is unlikely that there will be a steady influx of investment funds into major stocks.

Next week, there are 7 IPOs scheduled. On the 25th, ROXX <241A> will be listed on the growth market, ReplyOrity <242A> will be listed on the Fukuoka Q Board, and on the 26th, Growth Expert Partners <244A>, INGS <245A>, Asua <246A> (also listed on the Nagoya Stock Exchange), Kids Star <248A> will be listed on the growth market. On the 27th, Ai Robotics <247A> will be listed on the growth market. With the anticipation of investors due to the IPO for the first time in a month, Growth Expert Partners, which is engaged in enterprise DX support business, Kids Star, which is engaged in business development support through products for children, and Ai Robotics, which handles skincare products using AI systems, are likely to become popular. When IPO stocks become active, there is also a possibility that there will be an increase in the search for recent IPO stocks such as Oplo <228A> and Heartseed <219A>.